Literature DB >> 28239833

Outcomes of laparoscopic gastric bypass in a randomized clinical trial compared with a concurrent national database.

E Stenberg1, E Szabo1, J Ottosson1, I Näslund1.   

Abstract

BACKGROUND: RCTs are the standard for assessing medical interventions, but they may not be feasible and their external validity is sometimes questioned. This study aimed to compare results from an RCT on mesenteric defect closure during laparoscopic gastric bypass with those from a national database containing data on the same procedure, to shed light on the external validity of the RCT.
METHODS: Patients undergoing laparoscopic gastric bypass surgery within an RCT conducted between 1 May 2010 and 14 November 2011 were compared with those who underwent the same procedure in Sweden outside the RCT over the same time interval. Primary endpoints were severe complications within 30 days and surgery for small bowel obstruction within 4 years.
RESULTS: Some 2507 patients in the RCT were compared with 8485 patients in the non-RCT group. There were no differences in severe complications within 30 days in the group without closure of the mesenteric defect (odds ratio (OR) for RCT versus non-RCT 0·94, 95 per cent c.i. 0·64 to 1·36; P = 0·728) or in the group with closure of the defect (OR 1·34, 0·96 to 1·86; P = 0·087). There were no differences between the RCT and non-RCT cohorts in reoperation rates for small bowel obstruction in the mesenteric defect non-closure (cumulative incidence 10·9 versus 9·4 per cent respectively; hazard ratio (HR) 1·20, 95 per cent c.i. 0·99 to 1·46; P = 0·065) and closure (cumulative incidence 5·7 versus 7·0 per cent; HR 0·82, 0·62 to 1·07; P = 0·137) groups. The relative risk for small bowel obstruction without mesenteric defect closure compared with closure was 1·91 in the RCT group and 1·39 in the non-RCT group.
CONCLUSION: The efficacy of mesenteric defect closure was similar in the RCT and national registry, providing evidence for the external validity of the RCT.
© 2017 BJS Society Ltd Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2017        PMID: 28239833     DOI: 10.1002/bjs.10448

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  6 in total

1.  Alternative Method of Mesenteric Defect Closure after Roux-en-Y Gastric Bypass.

Authors:  Eugene Wang; Timothy Shope
Journal:  Obes Surg       Date:  2019-02       Impact factor: 4.129

2.  Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss at 5 Years Among Patients With Morbid Obesity: The SLEEVEPASS Randomized Clinical Trial.

Authors:  Paulina Salminen; Mika Helmiö; Jari Ovaska; Anne Juuti; Marja Leivonen; Pipsa Peromaa-Haavisto; Saija Hurme; Minna Soinio; Pirjo Nuutila; Mikael Victorzon
Journal:  JAMA       Date:  2018-01-16       Impact factor: 56.272

3.  Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss in Patients With Morbid Obesity: The SM-BOSS Randomized Clinical Trial.

Authors:  Ralph Peterli; Bettina Karin Wölnerhanssen; Thomas Peters; Diana Vetter; Dino Kröll; Yves Borbély; Bernd Schultes; Christoph Beglinger; Jürgen Drewe; Marc Schiesser; Philipp Nett; Marco Bueter
Journal:  JAMA       Date:  2018-01-16       Impact factor: 56.272

4.  Comparing Techniques for Mesenteric Defects Closure in Laparoscopic Gastric Bypass Surgery-a Register-Based Cohort Study.

Authors:  Erik Stenberg; Johan Ottosson; Eva Szabo; Ingmar Näslund
Journal:  Obes Surg       Date:  2019-04       Impact factor: 4.129

5.  Impact of mesenteric defect closure technique on complications after gastric bypass.

Authors:  Erik Stenberg; Ingmar Näslund; Eva Szabo; Johan Ottosson
Journal:  Langenbecks Arch Surg       Date:  2018-06-01       Impact factor: 3.445

6.  Association between metabolic surgery and cardiovascular outcome in patients with hypertension: A nationwide matched cohort study.

Authors:  Erik Stenberg; Yang Cao; Richard Marsk; Magnus Sundbom; Tomas Jernberg; Erik Näslund
Journal:  PLoS Med       Date:  2020-09-15       Impact factor: 11.069

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.